• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Ifosfamide--pharmacologic overview.

作者信息

Sarosy G

机构信息

Division of Cancer Treatment, National Cancer Institute, Bethesda, MD 20892.

出版信息

Semin Oncol. 1989 Feb;16(1 Suppl 3):2-8.

PMID:2649983
Abstract

Ifosfamide and its structural analogue cyclophosphamide are oxazaphosphorine nitrogen mustards, a group of compounds synthesized in West Germany more than 20 years ago. Whereas both chloroethyl groups of cyclophosphamide are attached to the same exocyclic nitrogen, one of ifosfamide's chloroethyl groups is attached to an endocyclic nitrogen. This minor structural change may account for the different pharmacologic behavior of these two compounds as well as their different spectrums of clinical activity and toxicity. Initial clinical trials of ifosfamide explored the use of a single intravenous dose. Hemorrhagic cystitis appeared to be dose-dependent and limited the use of this agent. However, the development of a systemic thiol uroprotector, such as mesna, has overcome this toxicity, permitting higher ifosfamide doses to be administered. Currently, ifosfamide is usually administered daily for five days in combination with mesna. The pharmacology and metabolism of ifosfamide may explain the toxicities associated with this compound and should be considered when designing schedules of administration.

摘要

相似文献

1
Ifosfamide--pharmacologic overview.
Semin Oncol. 1989 Feb;16(1 Suppl 3):2-8.
2
Ifosfamide and mesna.
Clin Pharm. 1990 Mar;9(3):179-91.
3
Continuous subcutaneous administration of mesna to prevent ifosfamide-induced hemorrhagic cystitis.持续皮下注射美司钠以预防异环磷酰胺所致出血性膀胱炎。
Semin Oncol. 1996 Jun;23(3 Suppl 6):97-8.
4
Pharmacology of ifosfamide.
Oncology. 2003;65 Suppl 2:2-6. doi: 10.1159/000073350.
5
Single-agent ifosfamide studies in sarcomas of soft tissue and bone: the M.D. Anderson experience.单药异环磷酰胺治疗软组织和骨肉瘤的研究:MD安德森癌症中心的经验
Cancer Chemother Pharmacol. 1993;31 Suppl 2:S174-9.
6
An overview of cyclophosphamide and ifosfamide pharmacology.环磷酰胺与异环磷酰胺药理学概述。
Pharmacotherapy. 1997 Sep-Oct;17(5 Pt 2):146S-154S.
7
Oral administration of mesna with ifosfamide.美司钠与异环磷酰胺联合口服给药。
Semin Oncol. 1996 Jun;23(3 Suppl 6):91-6.
8
Chemical stability and fate of the cytostatic drug ifosfamide and its N-dechloroethylated metabolites in acidic aqueous solutions.细胞抑制药物异环磷酰胺及其N-去氯乙基代谢物在酸性水溶液中的化学稳定性和归宿
J Med Chem. 1999 Jul 15;42(14):2542-60. doi: 10.1021/jm980587g.
9
Urine mesna excretion after intravenous and oral dosing in ifosfamide-treated children.
Cancer Chemother Pharmacol. 2004 Sep;54(3):237-40. doi: 10.1007/s00280-004-0801-6. Epub 2004 Jun 4.
10
Influence of mesna on urotoxic effects of selected bromosubstituted analogs of ifosfamide.
Arch Immunol Ther Exp (Warsz). 1997;45(1):79-85.

引用本文的文献

1
Renal toxicity and chemotherapy in children with cancer.癌症患儿的肾毒性与化疗
Br J Clin Pharmacol. 2017 Dec;83(12):2605-2614. doi: 10.1111/bcp.13388. Epub 2017 Sep 20.
2
Late effects on the urinary bladder in patients treated for cancer in childhood: a report from the Children's Oncology Group.儿童癌症患者膀胱的晚期效应:来自儿童肿瘤学组的报告。
Pediatr Blood Cancer. 2009 Apr;52(4):439-46. doi: 10.1002/pbc.21826.
3
Ifosfamide-related encephalopathy in elderly patients : report of five cases and review of the literature.
老年患者中与异环磷酰胺相关的脑病:5例报告及文献复习
Drugs Aging. 2007;24(11):967-73. doi: 10.2165/00002512-200724110-00008.
4
Preclinical pharmacokinetics and stability of isophosphoramide mustard.异环磷酰胺氮芥的临床前药代动力学与稳定性
Cancer Chemother Pharmacol. 1994;33(5):391-8. doi: 10.1007/BF00686268.
5
A prospective randomized evaluation of three schedules of mesna administration in patients receiving an ifosfamide-containing chemotherapy regimen: sustained efficiency and simplified administration.在接受含异环磷酰胺化疗方案的患者中对三种美司钠给药方案进行的前瞻性随机评估:持续有效性和简化给药。
J Cancer Res Clin Oncol. 1995;121(2):128-31. doi: 10.1007/BF01202226.
6
Toxicity of ifosfamide, cyclophosphamide and their metabolites in renal tubular cells in culture.异环磷酰胺、环磷酰胺及其代谢产物对培养的肾小管细胞的毒性作用。
Pediatr Nephrol. 1994 Apr;8(2):157-63. doi: 10.1007/BF00865466.
7
Ifosfamide pharmacokinetics.
Invest New Drugs. 1991 Nov;9(4):305-11. doi: 10.1007/BF00183570.
8
Ifosfamide/mesna. A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer.异环磷酰胺/美司钠。关于其抗肿瘤活性、药代动力学特性及在癌症治疗中疗效的综述。
Drugs. 1991 Sep;42(3):428-67. doi: 10.2165/00003495-199142030-00006.